Narcolepsy: Clinical features, co-morbidities & treatment

被引:0
|
作者
Peacock, Jeremy [1 ]
Benca, Ruth M. [1 ]
机构
[1] Univ Wisconsin, Dept Psychiat, Madison, WI 53706 USA
关键词
Cataplexy; excessive daytime sleepiness; hypocretin; MSLT; narcolepsy; EXCESSIVE DAYTIME SLEEPINESS; ONSET REM PERIODS; QUALITY-OF-LIFE; GAMMA-HYDROXYBUTYRATE; HLA DQB1-ASTERISK-0602; CEREBROSPINAL-FLUID; PRACTICE PARAMETERS; AMERICAN-ACADEMY; CATAPLEXY; MODAFINIL;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Narcolepsy is a neurologic illness that typically begins in the second and third decades of life. It is chronic in nature and negatively impacts the quality of life of affected patients. The classic presentation is a tetrad of excessive daytime sleepiness, cataplexy, sleep paralysis, and hypnagogic hallucinations. The exact cause remains unknown, but there is significant evidence that hypocretin deficiency plays an integral role. Some primary conditions that result in secondary narcolepsy include traumatic brain injury, congenital disorders, tumours, and strokes. Some medical and psychiatric disorders share characteristics of narcolepsy, at times leading to diagnostic inaccuracy. Other sleep disorders are commonly co-morbid. Diagnosis relies on patient history and objective data gathered from polysomnography and multiple sleep latency testing. Treatment focuses on symptom relief through medication, education, and behavioural modification. Both classic pharmacological treatments as well as newer options have significant problems, especially because of side effects and abuse potential. Novel modalities are being examined to expand options for treatment.
引用
收藏
页码:338 / 349
页数:12
相关论文
共 50 条
  • [1] Narcolepsy, co-morbidities and smoking
    Dhillon, Niku
    Riha, Renata
    Dhillon, Baljean
    SLEEP MEDICINE, 2018, 52 : 236 - 236
  • [2] Response to "smoking, co-morbidities and narcolepsy"
    Cohen, Alexander L.
    Mandrekar, Jay
    St Louis, Erik K.
    Silber, Michael H.
    Kotagal, Suresh
    SLEEP MEDICINE, 2018, 52 : 237 - 237
  • [3] Gout: Joints and beyond, epidemiology, clinical features, treatment and co-morbidities
    Robinson, Philip C.
    Horsburgh, Simon
    MATURITAS, 2014, 78 (04) : 245 - 251
  • [4] Assessment of clinical co-morbidities
    Basu, Debasish
    Basu, Aniruddha
    Ghosh, Abhishek
    INDIAN JOURNAL OF PSYCHIATRY, 2018, 60 (08) : 457 - 465
  • [5] Feline Hyperthyroidism - Treatment Options Co-morbidities
    von Fircks, Anna Lena
    von Luckner, Jennifer
    KLEINTIERPRAXIS, 2023, 68 (06): : 298 - 313
  • [6] CO-MORBIDITIES AND COMPLICATIONS OF DISEASE AND/OR TREATMENT: BONE
    McGinty, Tara
    Cotter, Aoife
    Sabin, Caroline
    Lambert, Jack
    Sheehan, Gerard
    Macken, Alan
    Kavanagh, Eoin
    Compston, Juliet
    Mallon, Paddy
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [7] Surgery with co-morbidities
    Oram, J
    Yates, A
    CURRENT ORTHOPAEDICS, 2004, 18 (05): : 379 - 395
  • [8] Co-morbidities in dementia: time to focus more on assessing and managing co-morbidities
    Subramaniam, Hari
    AGE AND AGEING, 2019, 48 (03) : 314 - 315
  • [9] The Role of Co-Morbidities
    Konstantinopoulou, Sofia
    Sideris, Georgios A.
    DelRosso, Lourdes M.
    CURRENT PROBLEMS IN PEDIATRIC AND ADOLESCENT HEALTH CARE, 2016, 46 (01) : 7 - 10
  • [10] Psoriasis and Co-morbidities
    Gulekon, Ayla
    Adisen, Esra
    TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, 2008, 42 : 23 - 25